Skip to content

Effectiveness of body skincare product containing a high, medium and low molecular weight levan for skin moisturizing : a triple-blind, three arms randomised controlled trial study protocol

Effectiveness of body skincare product containing a high, medium and low molecular weight levan for skin moisturizing : a triple-blind, three arms randomised controlled trial study protocol

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240717002
Enrollment
81
Registered
2024-07-17
Start date
2024-08-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Skin Levan Levansucrase Molecular weight Moisturizing effects Skin

Interventions

Volunteers will receive a skincare product containing high molecular weight Levan to apply to their forearms 2 times per day for a duration of 14 days.,Volunteers will receive a skincare product conta
Active Comparator Drug,Active Comparator Drug,Active Comparator Drug
body care products containing high molecular weight Levan,body care products containing medium molecular weight Levan,body care products containing Low molecular weight Levan

Sponsors

Burapha University, Chonburi, Thailand
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Thai volunteers, aged 20 years old and over, both male and female, and living in Chonburi Province. 2. People with dry skin

Exclusion criteria

Exclusion criteria: 1. People who have a history of allergic reactions to skin care products before. 2. People with inflammatory skin lesions, skin infection, wounds, or tumors on the skin 3. Pregnant and lactating women 4. Those who do not agree to stop using other skin care products on the forearm during participation in the research project

Design outcomes

Primary

MeasureTime frame
Skin hydration pre-trial,7 days and 14 days Corneometer CM825,Transepidermal water loss pre-trial,7 days and 14 days Tewameter TM300

Secondary

MeasureTime frame
Adverse Effect at 14 days Patient reported outcome using a questionnaire interview

Countries

Thailand

Contacts

Public ContactApiradee Vararungzarit

Faculty of Medicine, Burapha University

nphonja@buu.ac.th038386554

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026